Effect of octereotide in nonvariceal upper gastrointestinal bleeding

Phase 2

• Conditions: Condition 1: Upper GI bleeding. Condition 2: Upper GI bleeding. Condition 3: Upper GI bleeding.; Gastric ulcer; Duodenal ulcer; Peptic ulcer, site unspecified

• Registration Number: IRCT2015050322066N1
• Lead Sponsor: Vice Chancellor of Research, Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

inclusion criteria: Conscious patients; age between 18 to 80 years; with complaint of melena or hematemesis or tarry stools in rectal examination

Exclusion criteria: patients with congestive heart failure class 4; ESRD patients on hemodialysis; pregnant patients; Patients with acute coronary events; nursing patients; cirrhotic Patients with child score B or C; make any complications of treatment with Octreotide at any time during the study; the patient's willingness to withdraw from the study at any time during the study; taking any anticoagulant; patients suffering from coagulation diseases

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified